![]() | Up a level |
Pennell, D. and Porter, J.B. and Cappellini, M.D. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, Chi-Kong and Viprakasit, V. and Elalfy, M.S. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years. Blood, 116 (21). pp. 1735-1736.
Pennell, D.J. and Porter, J.B. and Cappellini, M.D. and El-Beshlawy, A. and Chan, L.L. and Aydinok, Y. and Elalfy, M.S. and Sutcharitchan, P. and Li, C.K. and Ibrahim, H. and Viprakasit, V. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood, 115 (12). pp. 2364-2371.
Cappellini, M.D. and Porter, J. and El-Beshlawy, A. and Li, C.K. and Seymour, J.F. and Elalfy, M. and Gattermann, N. and Giraudier, S. and Lee, J.W. and Chan, L.L. and Lin, K.H. and Rose, C. and Taher, A. and Thein, S.L. and Viprakasit, V. and Habr, D. and Domokos, G. and Roubert, B. and Kattamis, A. and Investigators, EPIC Study (2010) Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica-The Hematology Journal, 95 (4). pp. 557-566.